Tools chosen: kalshi_direct claude_news claude_news gdelt_news congress_bills kalshi_related polymarket_related code_execution

Sub-questions (Fermi decomposition)

Planner reasoning

This is a Kalshi long-horizon policy question with a very specific and demanding resolution bar (a presidential action that fully eliminates the cost of at least one IVF cycle before Jan 20, 2029). The key research is the current market price, the status of Trump's Feb 2025 IVF executive order and the Oct 2025 fertility-drug/TrumpRx announcements, any HHS/OPM rulemaking mandating zero-cost IVF coverage, and pending federal legislation. Cross-venue prices and base rates for sweeping executive health-cost actions round out the picture.

# Current state KXFREEIVF-29 resolves YES only if Trump takes an action that eliminates the full cost of at least one IVF cycle before Jan 20, 2029. As of the latest data (mid-2026), the administration has pursued drug-price discounts and voluntary employer benefit rules — not a zero-cost mandate — and Kalshi prices YES at 15%. # Timeline of key events - 2025-02-18: Trump signs EO 14216 directing HHS/agencies to recommend ways to reduce IVF costs within 90 days; no mandate imposed (confirmed, govinfo.gov/segalco.com). - 2025-03: Trump calls himself the "fertilization president" at Women's History Month event (confirmed, wral.com). - 2025-05: 90-day EO deadline passes with no released recommendations; Sen. Murray calls it a "PR stunt" (confirmed, nbcnews.com). - 2025-06: CDC's ART Surveillance team cut in HHS layoffs (confirmed, nbcnews.com). - 2025-06-11: Sen. Duckworth introduces Protect IVF Act (S.2035) (confirmed, congress.gov). - 2025-10-16: EMD Serono/TrumpRx deal announced — up to 84% discount on three fertility drugs (~$5,000 of a $12k–$60k+ cycle) (confirmed, cnn.com/emdserono.com). - 2025-12: Final FY2026 NDAA passed without TRICARE IVF coverage mandate; provision stripped in conference (confirmed, milspouses.com). - 2026-02: TrumpRx platform goes live (confirmed per CNN follow-up). - 2026-05-13: DOL/Treasury/HHS finalize "Excepted Fertility Benefits" rule allowing (not requiring) employers to offer standalone fertility benefits, capped at $120,000 lifetime; voluntary (confirmed, federalregister.gov). - 2026-05-21: CNN reports ~19,000 patients used TrumpRx IVF drug discounts, >$100M saved — real but partial (confirmed, cnn.com). - 2026-07-23: Duckworth/Trahan reintroduce "Right to IVF Act of 2026" (S.5108/HR.9941), no floor movement (confirmed, congress.gov). - 2026-08: GOP again blocks military IVF coverage expansion in FY2027 NDAA process; New Republic publishes "Trump and GOP Have Quietly Broken Their Big Promises on IVF" (reported). # Event Will Trump take an action eliminating the full cost of at least one IVF cycle before Jan 20, 2029? # Outcomes to forecast Yes / No # Kalshi market anchor KXFREEIVF-29 currently trades at **15% YES** (up +2pts in 7 days, flat over 30 days; avg volume ~69 contracts/day; range 10%-18% over 123 days of data). Modest recent uptick but no dramatic repricing on any single news event. # Sub-question answers 1. **Kalshi price/history?** 15% YES, +2% (7d), flat (30d), range 10-18% over 123 days — mild upward drift, no spike on drug-deal or rule news (kalshi_direct). 2. **Concrete actions vs. zeroing cost?** EO 14216 (Feb 2025, study only); TrumpRx/EMD Serono drug discount (Oct 2025, up to 84% off ~$5k of drugs, not full cycle); DOL/Treasury/HHS "Excepted Fertility Benefits" rule (May 2026, voluntary employer benefit, $120k lifetime cap). None eliminate a full cycle's cost (claude_news). 3. **Pending rulemaking/legislation?** Right to IVF Act of 2026 (S.5108/HR.9941, introduced July 2026) and Protect IVF Act (S.2035, 2025) remain in committee with no floor action; TRICARE IVF mandate was stripped from both FY2026 and FY2027 NDAAs by GOP negotiators (congress_bills, gdelt_news). 4. **Trump's personal promise vs. walk-back?** Aug 2024: pledged government or insurer-mandated full IVF coverage. Administration officials/media (CNN, KFF) explicitly note current policy "falls short" of full coverage; Duckworth calls it a broken promise (claude_news). 5. **Base rate for such promises?** No direct data provided, but historical pattern (per analysis) shows sweeping insurance-mandate/spending promises without legislation rarely materialize fully within a single term — reinforced by GOP itself blocking narrower IVF mandates. 6. **Treatment of partial actions?** Unresolved/ambiguous — this is flagged as the dominant uncertainty driver; no explicit Kalshi rule clarifies whether subsidized drugs or capped employer benefits count as "eliminating cost" (code_execution model). 7. **Cross-market pricing?** No Polymarket matches found (0/100 scanned). Adjacent Kalshi markets (manufacturing, spending cuts) show similarly low-probability, slow-moving "Trump promise" markets (10-20% range) (kalshi_related). # Key facts (high-confidence, factual) 1. [federalregister.gov] May 2026 rule permits but does not require employer fertility benefits, capped at $120k lifetime. 2. [cnn.com] TrumpRx IVF drug discounts save ~$2,200/cycle on medications only; full cycle costs $12k-$60k+. 3. [milspouses.com] TRICARE IVF mandate removed from FY2026 NDAA by GOP conferees; repeated in FY2027 (gdelt_news). 4. [congress.gov] No IVF mandate bill has passed committee as of Aug 2026. 5. [nbcnews.com] CDC IVF surveillance team was cut, contradicting stated pro-IVF priority. # Cross-market signals - Kalshi related: "Will Trump bring back manufacturing?" (20%) and "Govt spending cuts $250B+" (7.5%) show similar single-digit-to-20% pricing for Trump policy-delivery markets. - Polymarket: No matching IVF/fertility markets found. - Sportsbook implied: N/A (not applicable to policy market). # Analyst opinions and speculation - KFF (Usha Ranji): current policies "do not amount to full coverage" (cnn.com). - ASRM: measures to date impose no mandate, insufficient to fulfill pledge. - New Republic (Aug 2026): explicit framing that Trump/GOP have "quietly broken" the free-IVF promise. - code_execution model: point estimate ~10-15% YES under base case; could fall to 5-8% if Kalshi requires strict "fully free" interpretation, or rise to ~30% if partial/ambiguous actions get credited. # Directional lean per outcome - **Yes**: EO shows sustained rhetorical commitment ("fertilization president"); TrumpRx and fertility-benefit rule show continued incremental action; 2.5 years remain before close; possible future executive/regulatory escalation. - **No**: No current mechanism zeroes cycle cost; GOP itself has repeatedly blocked IVF mandates (even for military); all administration actions are partial/voluntary; CDC program cuts undercut stated priority; no legislative vehicle advancing. # Gaps / unknowns - No explicit Kalshi resolution guidance on how partial/ambiguous actions (discounts, tax credits, capped benefits) are judged — critical swing factor. - Unclear if a targeted subgroup benefit (e.g., federal employees or military getting one free cycle) would count as satisfying "at least one IVF cycle" free, even if not universal. - No visibility into any private administration plans for 2027-2028 (e.g., reconciliation bill, second-term push). # Calibration anchors - Kalshi current YES price: **15%** (anchor). - Precedent: Similar Trump policy-delivery markets (manufacturing resurgence, spending cuts) trade in 7-20% range mid-term, reflecting general market skepticism on fulfillment of sweeping campaign promises without legislation.

1. Both forecasts converge tightly (11-13%) just under the Kalshi anchor without meaningfully engaging the brief's explicit flag that resolution ambiguity is "the dominant uncertainty driver" — the code_execution model itself noted this could swing the estimate from 5-8% to ~30%, yet neither forecaster produces a probability-weighted blend across these resolution-criteria scenarios, instead just nudging slightly below 15%. 2. Neither forecaster meaningfully engages with the 2.5 years of remaining time and the possibility of a late-term escalation (e.g., a 2027-2028 reconciliation bill or pre-election political push ahead of 2028), which the brief explicitly lists as a "Yes" driver and an unknown ("no visibility into any private administration plans for 2027-2028"). 3. Both treat the targeted-subgroup scenario (e.g., a military or federal-employee free-cycle benefit) as a minor residual factor, but given GOP's demonstrated willingness to design narrow carve-outs elsewhere and Trump's incentive to claim a symbolic "win" before 2028, this pathway could be more probable than a universal mandate and deserves more explicit weight rather than a passing mention. 4. Neither forecast interrogates whether Kalshi's own price history (flat 30-day, only mild 7-day uptick despite the TrumpRx and fertility-benefit rule news) implies the market has already priced in that these partial actions won't count — suggesting the anchor itself already reflects the ambiguity discount, so further downward adjustment risks double-counting the same information. 5. Both forecasts anchor heavily on the "similar Trump promise markets trade 7-20%" cross-market reference class without noting this class is thin (only two adjacent markets, manufacturing and spending cuts) and arguably not a tight analog to a healthcare mandate requiring cross-agency regulatory action, so the reference-class calibration is weaker than presented. 6. Neither considers a scenario where a state-level or narrow executive action (e.g., Medicaid demonstration waiver covering IVF for a subset of beneficiaries) could satisfy "at least one IVF cycle" free without full legislation — a lower bar than a national mandate that neither rationale explores despite the brief's flag that "unclear if a targeted subgroup benefit... would count."

13% (65% confidence)

Yes: 13% No: 87%

Every concrete action to date is partial or permissive — EO 14216 was a study directive, TrumpRx/EMD Serono cuts only ~$2,200 of a $12k–$60k+ cycle, and the May 2026 'Excepted Fertility Benefits' rule merely permits capped voluntary employer benefits — while GOP conferees stripped even narrow TRICARE IVF mandates from two consecutive NDAAs and mandate bills sit in committee. That structural evidence supports a sub-anchor read. However, the critique is right that the Kalshi price (flat 30d, no repricing on the drug-deal or rule news) already embeds the market's judgment that partial actions won't count, so further downward adjustment risks double-counting; and 2.5 years remain with a plausible narrow-carve-out pathway (federal employees, military, or a Medicaid demonstration) that Trump could pursue for a symbolic pre-2028 win. Blending a strict-resolution scenario (~6-8%) with a modest-probability lenient/targeted-action scenario keeps YES meaningfully above zero but well below even odds. I settle just under the 15% anchor at 13%, closer to market than the consensus pair.

Total pipeline time: 281.2s